Astrazeneca PLC (AZN) Scheduled to Post Quarterly Earnings on Thursday
Astrazeneca PLC (NYSE:AZN) is scheduled to be announcing its earnings results before the market opens on Thursday, November 9th. Analysts expect the company to announce earnings of $0.53 per share for the quarter.
ILLEGAL ACTIVITY WARNING: This story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://theolympiareport.com/2017/11/02/astrazeneca-plc-azn-scheduled-to-post-quarterly-earnings-on-thursday.html.
AZN has been the topic of a number of research analyst reports. Argus reaffirmed a “buy” rating and set a $35.00 price objective on shares of Astrazeneca PLC in a research report on Friday, September 1st. Investec raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. Natixis raised shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Friday, September 22nd. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $35.10.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.